Literature DB >> 23218472

Achieving breast cancer surgery in a single setting with intraoperative frozen section analysis of the sentinel lymph node.

Qinghui Lu1, Ern-Yu Tan, Bernard Ho, Christine Teo, Melanie D W Seah, Juliana J C Chen, Patrick M Y Chan.   

Abstract

BACKGROUND: Current guidelines recommend full axillary lymph node dissection (ALND) whenever the SLN is positive for metastases. In our institute, we aim to complete surgery in a single setting and base the decision for ALND on the intraoperative FS analysis of the SLN. In this study, we evaluate the efficacy this practice in terms of the accuracy of FS analysis, patient recall rate, and additional time required for FS analysis.
MATERIALS AND METHODS: Retrospective review was performed of 586 patients who underwent SLN biopsy at our institution from January 1, 2006 to December 31, 2010. Intraoperative FS analysis was routinely performed in all cases with a preoperative diagnosis of invasive breast cancer and in selected cases of ductal carcinoma in situ according to surgeon preference.
RESULTS: The SLN was positive for metastases in 123 (22.7%) patients; this was identified on FS analysis in 107 patients. FS analysis had a sensitivity of 87.0% and specificity of 100% and resulted in a patient recall rate of 3%. Micrometastasis accounted for most of the false negative FS results. These deposits were mostly detected only on deeper sectioning of the permanent sections of the SLN. An invasive lobular histology and lymphovascular invasion were found to be independent predictors of a false negative FS on multivariate analysis (P < .01). Intraoperative FS did not significantly prolong operating times.
CONCLUSION: Intraoperative FS analysis is an accurate and efficient means of rapid SLN assessment and allows ALND to be completed in a single setting.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23218472     DOI: 10.1016/j.clbc.2012.11.005

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  6 in total

1.  False Negative Rate of Sentinel Lymph Node Biopsy on Intraoperative Frozen Section in Early Breast Cancer Patients: An Institutional Experience.

Authors:  Sandhya Gupta; Geeta Kadayaprath; Rooma Ambastha; Shakti Saumnam Shrivastava
Journal:  Indian J Surg Oncol       Date:  2021-10-05

2.  Axillary Lymph Node Dissection Can Be Omitted in Breast Cancer Patients With Mastectomy and False-Negative Frozen Section in Sentinel Lymph Node Biopsy.

Authors:  Jing Si; Rong Guo; Huan Pan; Xiang Lu; Zhiqin Guo; Chao Han; Li Xue; Dan Xing; Wanxin Wu; Caiping Chen
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

Review 3.  Sentinel lymph nodes for breast carcinoma: an update on current practice.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

4.  Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer Patients Post-Neoadjuvant Therapy.

Authors:  Willard Wong; Illana Rubenchik; Sharon Nofech-Mozes; Elzbieta Slodkowska; Carlos Parra-Herran; Wedad M Hanna; Fang-I Lu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

5.  Evaluation of Intraoperative Frozen Section Analysis with Final Histopathology Results for Sentinel Lymph Node Biopsy: Z0011 Criteria Eligible Versus Ineligible Breast Cancer Patients.

Authors:  Florian Reinhardt; Anna Fiedler; Felix Borgmeier; Petra Reinecke; Irene Esposito; Katalin Mattes-György; Mardjan Dabir; Verena Friebe; Natalia Krawczyk; Thomas Kaleta; Jürgen Hoffmann; Eugen Ruckhäberle; Tanja Fehm; Katrin S Roth; Svjetlana Mohrmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-06-03       Impact factor: 2.754

6.  False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients.

Authors:  Zhu-Jun Loh; Kuo-Ting Lee; Ya-Ping Chen; Yao-Lung Kuo; Wei-Pang Chung; Ya-Ting Hsu; Chien-Chang Huang; Hui-Ping Hsu
Journal:  World J Surg Oncol       Date:  2021-06-22       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.